arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

BRISTOL MYERS SQUIBB CO

BMY
$64.69 ▲ +0.53 (+0.83%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
75 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
68
Health
Good
Neutral
auto_awesome

Analytical Summary

BRISTOL MYERS SQUIBB CO shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $132.1B
Dividend Yield 0.97%
Revenue Growth 5.7%
Op. Margin None
ROIC None
FCF / Share $1.51
Trailing P/E 39.9x
Price / Book 5.9x
FCF Yield 2.3%
Debt / Equity 1.97
info Valuation on last close. End-of-day price, Aug 7, 2026.

75-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$12.97B
↑ +5.7%
Net Income Profit after all expenses
$3.32B
↑ +153.2%
FCF / Share Free cash flow per share
$1.51
↑ +307.1%
Long-Term Debt Long-term obligations
$42.86B
↓ -2.9%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
82
Returns
95
Financial Health
10
Cash Quality
84

Dividend History

Dividend / share · sourced from SEC filings
$2.49 Latest / share
+2.9% YoY
+5.0% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 20 years · 75 quarters